These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

305 related items for PubMed ID: 31434140

  • 1. Ketamine in the Treatment of Depressive Episodes.
    Ritter P, Findeis H, Bauer M.
    Pharmacopsychiatry; 2020 Mar; 53(2):45-50. PubMed ID: 31434140
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.
    Popova V, Daly EJ, Trivedi M, Cooper K, Lane R, Lim P, Mazzucco C, Hough D, Thase ME, Shelton RC, Molero P, Vieta E, Bajbouj M, Manji H, Drevets WC, Singh JB.
    Am J Psychiatry; 2019 Jun 01; 176(6):428-438. PubMed ID: 31109201
    [Abstract] [Full Text] [Related]

  • 3. Antisuicidal and antidepressant effects of ketamine and esketamine in patients with baseline suicidality: A systematic review.
    Siegel AN, Di Vincenzo JD, Brietzke E, Gill H, Rodrigues NB, Lui LMW, Teopiz KM, Ng J, Ho R, McIntyre RS, Rosenblat JD.
    J Psychiatr Res; 2021 May 01; 137():426-436. PubMed ID: 33774537
    [Abstract] [Full Text] [Related]

  • 4. Ketamine for depression clinical issues.
    Iqbal SZ, Mathew SJ.
    Adv Pharmacol; 2020 May 01; 89():131-162. PubMed ID: 32616205
    [Abstract] [Full Text] [Related]

  • 5. A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
    Naughton M, Clarke G, O'Leary OF, Cryan JF, Dinan TG.
    J Affect Disord; 2014 Mar 01; 156():24-35. PubMed ID: 24388038
    [Abstract] [Full Text] [Related]

  • 6. Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial.
    Smith-Apeldoorn SY, Veraart JKE, Kamphuis J, van Asselt ADI, Touw DJ, Aan Het Rot M, Schoevers RA.
    BMC Psychiatry; 2019 Nov 29; 19(1):375. PubMed ID: 31783823
    [Abstract] [Full Text] [Related]

  • 7. KETAMINE FOR TREATMENT-RESISTANT UNIPOLAR AND BIPOLAR MAJOR DEPRESSION: CRITICAL REVIEW AND IMPLICATIONS FOR CLINICAL PRACTICE.
    Bobo WV, Vande Voort JL, Croarkin PE, Leung JG, Tye SJ, Frye MA.
    Depress Anxiety; 2016 Aug 29; 33(8):698-710. PubMed ID: 27062450
    [Abstract] [Full Text] [Related]

  • 8. Antidepressant Efficacy and Tolerability of Ketamine and Esketamine: A Critical Review.
    Molero P, Ramos-Quiroga JA, Martin-Santos R, Calvo-Sánchez E, Gutiérrez-Rojas L, Meana JJ.
    CNS Drugs; 2018 May 29; 32(5):411-420. PubMed ID: 29736744
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1).
    Fedgchin M, Trivedi M, Daly EJ, Melkote R, Lane R, Lim P, Vitagliano D, Blier P, Fava M, Liebowitz M, Ravindran A, Gaillard R, Ameele HVD, Preskorn S, Manji H, Hough D, Drevets WC, Singh JB.
    Int J Neuropsychopharmacol; 2019 Oct 01; 22(10):616-630. PubMed ID: 31290965
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of intranasal esketamine for the treatment of major depressive disorder.
    Kryst J, Kawalec P, Pilc A.
    Expert Opin Pharmacother; 2020 Jan 01; 21(1):9-20. PubMed ID: 31663783
    [Abstract] [Full Text] [Related]

  • 11. Comparative effectiveness of esketamine in the treatment of anhedonia in bipolar and unipolar depression.
    Delfino RS, Del-Porto JA, Surjan J, Magalhães E, Sant LCD, Lucchese AC, Tuena MA, Nakahira C, Fava VAR, Steglich MS, Barbosa MG, Sarin LM, Lacerda ALT.
    J Affect Disord; 2021 Jan 01; 278():515-518. PubMed ID: 33017679
    [Abstract] [Full Text] [Related]

  • 12. Relapse prevention in treatment-resistant major depressive disorder with rapid-acting antidepressants.
    Singh JB, Fedgchin M, Daly EJ, Drevets WC.
    Adv Pharmacol; 2020 Jan 01; 89():237-259. PubMed ID: 32616208
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of Esketamine Augmentation in Major Depressive Disorder: A Meta-Analysis.
    Papakostas GI, Salloum NC, Hock RS, Jha MK, Murrough JW, Mathew SJ, Iosifescu DV, Fava M.
    J Clin Psychiatry; 2020 May 26; 81(4):. PubMed ID: 32459407
    [Abstract] [Full Text] [Related]

  • 14. Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation.
    McIntyre RS, Rosenblat JD, Nemeroff CB, Sanacora G, Murrough JW, Berk M, Brietzke E, Dodd S, Gorwood P, Ho R, Iosifescu DV, Lopez Jaramillo C, Kasper S, Kratiuk K, Lee JG, Lee Y, Lui LMW, Mansur RB, Papakostas GI, Subramaniapillai M, Thase M, Vieta E, Young AH, Zarate CA, Stahl S.
    Am J Psychiatry; 2021 May 01; 178(5):383-399. PubMed ID: 33726522
    [Abstract] [Full Text] [Related]

  • 15. Rapid and longer-term antidepressant effects of repeated-dose intravenous ketamine for patients with unipolar and bipolar depression.
    Zheng W, Zhou YL, Liu WJ, Wang CY, Zhan YN, Li HQ, Chen LJ, Li MD, Ning YP.
    J Psychiatr Res; 2018 Nov 01; 106():61-68. PubMed ID: 30278319
    [Abstract] [Full Text] [Related]

  • 16. Rapid antidepressant effects of repeated doses of ketamine compared with electroconvulsive therapy in hospitalized patients with major depressive disorder.
    Ghasemi M, Kazemi MH, Yoosefi A, Ghasemi A, Paragomi P, Amini H, Afzali MH.
    Psychiatry Res; 2014 Feb 28; 215(2):355-61. PubMed ID: 24374115
    [Abstract] [Full Text] [Related]

  • 17. Ketamine in depression and electroconvulsive therapy.
    Rozet I.
    Curr Opin Anaesthesiol; 2021 Oct 01; 34(5):556-562. PubMed ID: 34435599
    [Abstract] [Full Text] [Related]

  • 18. Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis.
    Bahji A, Vazquez GH, Zarate CA.
    J Affect Disord; 2021 Jan 01; 278():542-555. PubMed ID: 33022440
    [Abstract] [Full Text] [Related]

  • 19. Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent: Double-Blind, Randomized Study (ASPIRE I).
    Fu DJ, Ionescu DF, Li X, Lane R, Lim P, Sanacora G, Hough D, Manji H, Drevets WC, Canuso CM.
    J Clin Psychiatry; 2020 May 12; 81(3):. PubMed ID: 32412700
    [Abstract] [Full Text] [Related]

  • 20. Ketamine for Depression, 2: Diagnostic and Contextual Indications.
    Andrade C.
    J Clin Psychiatry; 2017 May 12; 78(5):e555-e558. PubMed ID: 28570803
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.